ATE546526T1 - Hybrid-interferenz-rna - Google Patents

Hybrid-interferenz-rna

Info

Publication number
ATE546526T1
ATE546526T1 AT06743972T AT06743972T ATE546526T1 AT E546526 T1 ATE546526 T1 AT E546526T1 AT 06743972 T AT06743972 T AT 06743972T AT 06743972 T AT06743972 T AT 06743972T AT E546526 T1 ATE546526 T1 AT E546526T1
Authority
AT
Austria
Prior art keywords
interference rna
hybrid interference
hybrid
rna
molecule
Prior art date
Application number
AT06743972T
Other languages
English (en)
Inventor
Josephine Anne Milner
Michael Gait
Ming Jiang
Andrei Arzumanov
Original Assignee
Univ York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0510612A external-priority patent/GB0510612D0/en
Priority claimed from GB0510617A external-priority patent/GB0510617D0/en
Priority claimed from GB0516191A external-priority patent/GB0516191D0/en
Priority claimed from GB0516193A external-priority patent/GB0516193D0/en
Application filed by Univ York filed Critical Univ York
Application granted granted Critical
Publication of ATE546526T1 publication Critical patent/ATE546526T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
AT06743972T 2005-05-25 2006-05-24 Hybrid-interferenz-rna ATE546526T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0510612A GB0510612D0 (en) 2005-05-25 2005-05-25 Polymerase chain reaction
GB0510617A GB0510617D0 (en) 2005-05-25 2005-05-25 Hybrid interfering RNA
GB0516191A GB0516191D0 (en) 2005-08-06 2005-08-06 Polymerase chain reaction
GB0516193A GB0516193D0 (en) 2005-08-06 2005-08-06 Hybrid interfering rna
PCT/GB2006/001895 WO2006125977A2 (en) 2005-05-25 2006-05-24 Hybrid interfering rna

Publications (1)

Publication Number Publication Date
ATE546526T1 true ATE546526T1 (de) 2012-03-15

Family

ID=37420934

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06743972T ATE546526T1 (de) 2005-05-25 2006-05-24 Hybrid-interferenz-rna

Country Status (4)

Country Link
US (2) US8067572B2 (de)
EP (1) EP1891216B1 (de)
AT (1) ATE546526T1 (de)
WO (1) WO2006125977A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1304768B1 (it) * 1998-10-05 2001-03-29 Esaote Spa Lettino porta paziente o simili, e macchina, in particolare macchinaper il rilevamento d'immagini in risonanza magnetica nucleare in
WO2006125977A2 (en) * 2005-05-25 2006-11-30 The University Of York Hybrid interfering rna
GB0716072D0 (en) * 2007-08-17 2007-09-26 Univ York Therapy
WO2010017544A2 (en) * 2008-08-08 2010-02-11 Genisphere, Inc. Long-acting dna dendrimers and methods thereof
EP2379083B1 (de) * 2008-12-18 2017-08-16 Dicerna Pharmaceuticals, Inc. Verlängerte dicer-substratstoffe und verfahren für spezifische genexpressionshemmung
ES2845212T3 (es) 2009-04-13 2021-07-26 Inst Nat Sante Rech Med Partículas de HPV y usos de las mismas
EP2562257A4 (de) * 2010-04-19 2014-10-01 Riken Verfahren zur stabilisierung funktioneller nukleinsäuren
US20110306653A1 (en) * 2010-05-14 2011-12-15 Tagcyx Biotechnologies Stabilization method of functional nucleic acid
WO2012014945A1 (ja) * 2010-07-28 2012-02-02 国立大学法人北海道大学 アジュバント活性を有する新規核酸およびその利用
WO2012016139A2 (en) * 2010-07-29 2012-02-02 Sirnaomics, Inc. Sirna compositions and methods for treatment of hpv and other infections
EP2631291B1 (de) 2010-10-22 2019-05-15 OliX Pharmaceuticals, Inc. Nukleinsäuremoleküle zur induzierung einer rna-interferenz und verwendungen davon
EP2770054A4 (de) * 2011-10-19 2015-09-02 Riken Aktivierung funktioneller nukleinsäuren durch spezifische modifikation
US9700639B2 (en) 2012-02-07 2017-07-11 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
DK2853597T3 (en) 2012-05-22 2019-04-08 Olix Pharmaceuticals Inc RNA INTERFERENCE-INducing NUCLEIC ACID MOLECULES WITH CELL PENETENING EQUIPMENT AND USE THEREOF
US20160051693A1 (en) 2013-03-21 2016-02-25 Genisphere, Llc Cellular Delivery of DNA Intercalating Agents
EP4059521A1 (de) 2013-09-18 2022-09-21 Aura Biosciences, Inc. Virusähnliche partikelkonjugate zur diagnose und behandlung von tumoren
CN108473950A (zh) 2015-10-30 2018-08-31 美国政府卫生与公众服务部 靶向癌症治疗
EP3377630A4 (de) 2015-11-16 2020-01-01 Olix Pharmaceuticals, Inc. Behandlung von altersbedingter makuladegeneration mit auf myd88 oder tlr3 abzielenden rna-komplexen
EP3411481A4 (de) 2016-02-02 2020-02-26 Olix Pharmaceuticals, Inc. Behandlung von angiogeneseassoziierten erkrankungen mit auf angpt2 und pdgfb abzielenden rna-komplexen
JP6944942B2 (ja) 2016-02-02 2021-10-06 オリックス ファーマシューティカルズ，インコーポレーテッド ＩＬ４Ｒα、ＴＲＰＡ１、またはＦ２ＲＬ１を標的とするＲＮＡ複合体を用いたアトピー性皮膚炎および喘息の治療
IL260983B (en) 2016-02-19 2022-07-01 Genisphere Llc Nucleic acid carriers and methods of medical use
WO2017178883A2 (en) 2016-04-11 2017-10-19 Olix Pharmaceuticals, Inc. Treatment of idiopathic pulmonary fibrosis using rna complexes that target connective tissue growth factor
KR101916652B1 (ko) 2016-06-29 2018-11-08 올릭스 주식회사 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
EP3580339A4 (de) 2017-02-10 2020-12-23 Research & Business Foundation Sungkyunkwan University Lange doppelsträngige rna für rna-interferenz
CA3059882A1 (en) 2017-04-12 2018-10-18 Aura Biosciences, Inc. Targeted combination therapy
CN113454221A (zh) * 2018-12-12 2021-09-28 迪克纳制药公司 含有三元环的双链核酸抑制剂分子
WO2021001646A2 (en) * 2019-07-02 2021-01-07 Argonaute RNA Limited Apolipoprotein b antagonist
CN110269014B (zh) * 2019-07-23 2021-01-12 中国海洋大学 一种单环刺螠幼虫的rna干扰方法
CA3167849A1 (en) * 2020-03-16 2021-09-23 Daniel Mitchell Antagonist of pcsk9
GB202020534D0 (en) * 2020-12-23 2021-02-03 Argonaute Rna Ltd Conjugate
US20250304966A1 (en) * 2020-12-23 2025-10-02 Argonaute RNA Limited Treatment of cardiovascular disease
KR20230154026A (ko) * 2021-02-08 2023-11-07 락티젠 세러퓨틱스 다가 올리고뉴클레오티드 작용제 및 이의 사용 방법
EP4402263A2 (de) * 2021-09-14 2024-07-24 Argonaute Rna Limited Behandlung von herz-kreislauf-erkrankungen
GB2618915B (en) * 2022-05-18 2024-08-14 Argonaute Rna Ltd Treatment of cardiovascular disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206887A1 (en) * 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
EP1432799A2 (de) * 2001-07-17 2004-06-30 Anne Josephine Milner Abschaltung der genexpression durch sirna
US20030194718A1 (en) * 2002-04-15 2003-10-16 Hitachi. Ltd. Probing sequence determination system for DNA arrays
DE60331580D1 (de) * 2002-11-18 2010-04-15 Panomics Inc Caged-sensoren, -regulatoren und-verbindungen sowie verwendungen davon
JP2004261002A (ja) * 2003-01-08 2004-09-24 Tsutomu Suzuki ｓｉＲＮＡの製造方法
US7407784B2 (en) * 2003-01-20 2008-08-05 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. L-amino acid oxidase with cytotoxic activity from Aplysia punctata
EP1844147A2 (de) * 2005-01-18 2007-10-17 Sirna Therpeutics, Inc. Durch rna-interferenz vermittelte inhibition von retinoblastina-genexpression unter verwendung von short-interfering-nukleinsäure
WO2006125977A2 (en) * 2005-05-25 2006-11-30 The University Of York Hybrid interfering rna

Also Published As

Publication number Publication date
US20090012022A1 (en) 2009-01-08
US8067572B2 (en) 2011-11-29
US20120136040A1 (en) 2012-05-31
WO2006125977A2 (en) 2006-11-30
EP1891216B1 (de) 2012-02-22
WO2006125977A3 (en) 2007-01-25
EP1891216A2 (de) 2008-02-27

Similar Documents

Publication Publication Date Title
WO2006125977A3 (en) Hybrid interfering rna
BRPI0819193A2 (pt) uso de oligonucleotídeos com bases modificadas na hibridização de ácidos nucleicos.
MX2008008261A (es) Intercambio nucleotidico dirigido mejorado con oligonucleotidos modificados por lna.
EP1731525A4 (de) Nukleotidderivate und dna-mikroarray
DK1713912T3 (da) Modificerede Korte Interfererende RNA (Modificerede siRNA)
EP2294195A4 (de) Oligonukleotid-duplexe mit dna-ähnlichen und rna-ähnlichen nukleotiden und verwendungen dafür
EP2089517A4 (de) Polymeraseenzyme und reagenzien für erweiterte nukeinsäuresequenzierung
EP1723162A4 (de) Anti-mikrorna-oligonukleotidmoleküle
EP2064223A4 (de) Duplexoligonukleotide und verfahren zum gen-silencing durch rna-interferenz
EP1646639B8 (de) Nucleotid-phosphoramidate als antikrebs- verbindungen
PL1807520T3 (pl) Konstrukty do RNA
ATE542922T1 (de) 2'-terminator-assoziierte pyrophosphorolyse- aktivierte polymerisierung
ATE502122T1 (de) Chemisch modifizierte oligonukleotidprimer zur nukleinsäureamplifikation
WO2009039189A3 (en) Compositions comprising stat3 sirna and methods of use thereof
WO2008087641A3 (en) H19 silencing nucleic acid agents for treating rheumatoid arthritis
WO2005049832A3 (en) FcϜRIIA-SPECIFIC NUCLEIC ACID INTERFERENCE
WO2008016906A3 (en) 3'-phosphate-labeled nucleotide analogs and their use for sequencing a nucleic acid
DE602005027253D1 (de) Herbizidresistenz verleihende gene
WO2007014077A3 (en) Rnai modulation of the rho-a gene and uses thereof
EP2157182A3 (de) Modifizierte kurz interferierende RNA
ATE407939T1 (de) 2ß-NITROBENZYL-MODIFIZIERTE RIBONUKLEOTIDE
IL197415A0 (en) Azole nucleosides and use as inhibitors of rna and dna varial polymerases
GB0621361D0 (en) Use of DNA polymerases
WO2007084359A3 (en) Compositions and methods for the treatment of influenza infection
IL189540A0 (en) Chemically modified short interfering nucleic acid molecules that mediate rna interference